2017_4q_omron_e
33/57 - Core Technologies Fields to be Further Strengthened
【テロップ】
※各テロップ文字をクリックすると該当の場所がピンポイントで閲覧できます。
00:32:49.0
Furthermore, we recently announced a business and capital alliance with AliveCor of the US. AliveCor is the first device maker to receive FDA approval for a mobile cardiograph capable of detecting atrial fibrillation (AF). AF is considered to be a dangerous form of arrhythmia that can lead to the creation of potentially life-threatening blood clots associated with ischemic strokes. In addition to this mobile cardiograph, AliveCor also has a remote monitoring platform for cardiologists and patients. In tandem with the wearable BPM technology we are currently developing, we will work together with AliveCor to develop a new combined wearable cardiograph and BPM. We envision a product that will look like the image on the right-hand side of the slide. We will also jointly develop a service platform that uses cardiogram and blood pressure data. At this time, no one has developed devices or services like these. We are changing our business model to ensure that we will be the first with this product and service. This covers the FA and Healthcare initiatives. Next I will talk about firm-wide initiatives and the reinforcement of our core technologies. Please turn to slide 32.
【ノート】